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In this issue, Patricelli et al. (2011) describe an in situ chemoproteomics approach (KiNativ) for profiling
the kinome and kinome response to specific kinase inhibitors that enables characterization of inhibitor
interactions with endogenously expressed kinases in native conditions.Protein kinases are involved in the regula-
tion of a broad range of cellular processes
and are shown to have intimate relation-
ships with the pathogenesis of many
human diseases. Accordingly, kinase in-
hibitors have emerged both as indispensi-
ble tools for elucidation of the biological
functions of kinases and as therapeutic
agents for molecular-targeted therapy
(Dar and Shokat, 2010). In fact, based on
the promise of drugs such as Gleevec/
imatinib, which neutralizes BCR-Abl for
the treatment of chronic myelogenous
leukemia, and PLX-4720, which targets
the V600E mutant of B-Raf that occurs
frequently in melanoma, there continues
to be intense interest in the discovery
of new kinase inhibitors. Despite some
successes, the development of novel
inhibitors and the identification of their
bonafide cellular targets remain major
challenges. A major obstacle relates to
the shared architecture and catalytic
mechanism for the 500 or so protein
kinases that are encoded within the
human genome. In this respect, many
inhibitors that are currently available are
directed against the catalytic or ATP site
of kinases, raising the prospect of off-
target interactions with the many other
kinases or other ATP-binding proteins
that are present in cells. Accordingly, the
design of selective kinase inhibitors typi-
cally requires detailed knowledge of the
kinase target, including structural informa-
tion andunderstandingof its regulation, as
well as information regarding its oligomer-
ization state and binding partner interac-
tions (Dar andShokat, 2010). Anadditional
complication is highlighted by the recent,
somewhat paradoxical observations that,
in some instances, ATP-competitive
kinase inhibitors can act as activators of
the pathways that they were intended toinhibit. This is the case for the Raf kinase
inhibitors (PLX4720, GDC-0879) that do
effectively inhibit Raf signaling in cells ex-
pressing B-V600E Raf mutants (Hatzivas-
siliou et al., 2010; Poulikakos et al., 2010).
By comparison, in cells expressing wild-
type B-Raf through a mechanism that
involves inhibitor-induced dimerization
between B-Raf and C-Raf (Raf-1), these
inhibitors actually ‘‘prime’’ the activation
of these complexes, leading to enhanced
ERK/MAPK signaling in cells. Similar
observations have been made with Akt
and other AGC family kinases (Frye and
Johnson, 2009). Overall, these findings
demonstrate that kinase inhibitors can
act in a cell context-dependent manner.
Over the past decade, many powerful
technologies have been developed to
characterize kinase inhibitor selectivity
and identify kinase inhibitor targets.
These approaches have involved the
immobilization of kinase inhibitors or
ATP onto solid supports to enable the
affinity capture of kinases. For example,
in the studies described by Karaman
et al. (2008), competition experiments
performed with selected kinase inhibitors
defined the relative binding affinities and
specific kinase interaction profiles for
these inhibitors. While these studies
revealed considerable detail regarding
the selectivity and specificity of ATP-
competitive kinase inhibitors (including
dasatinib, lapatinib, and imatinib), these
studies were highly dependent on the
use of recombinant expressed kinase
domains. By comparison, other ap-
proaches have involved screening for
interactions with endogenous kinases
using immobilized selective or pan kinase
inhibitors (kinobeads) and quantitative
mass spectrometry (Godl et al., 2003;
Bantscheff et al., 2007; Sharma et al.,Chemistry & Biology 18, June 24, 20112009). This highly effective approach
has provided considerable insight into
the effects of inhibitors on the kinome
of multiple disease models. A comple-
mentary method (KiNativ) employs highly
reactive biotinlyated acyl phosphate
derivatives of ATP and ADP as an affinity
tagging approach to capture large
numbers of native kinases from cells
(Patricelli et al., 2007).
In the new study by Patricelli et al.
(2011), the utility of the KiNativ approach
has been extended to enable evaluation
of the functionally relevant properties of
kinase inhibitors on native kinases. In
short, the authors developed a targeted
mass spectrometry approach to interro-
gate the acyl phosphate-tagged kinome
from cell lysates. Using a list of selected
peptide kinase fragment ions and linear
ion trap mass spectrometry, the authors
report enhanced detection and quantifi-
cation of more than 150 probe-labeled
kinases from a chosen proteome. Thus,
these studies represent one of the most
comprehensive, direct analyses of ATP-
binding sites of the native kinome per-
formed to date. Furthermore, by perform-
ing the acylation reactions in the presence
of kinase inhibitors, it was possible to
obtain apparent binding constants for
inhibitors with specific kinases.
Of significance in this study, the
authors provide evidence that the re-
sponse to kinase inhibitors depends on
both the cellular context and the native
properties of the endogenous kinase.
This is most clearly demonstrated with
epidermal growth factor receptor (EGFR),
mitogen-activated protein kinase kinase
5 (MAP2K5), and Raf kinases. For EGFR,
the authors show that the potency of
erlotinib was highly dependent on the
context of the receptor (i.e., intact versusª2011 Elsevier Ltd All rights reserved 683
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Previewsolubilized membranes). Only with the
intact membranes did the potency of
erlotinib match the cellular efficacy of
this inhibitor. These studies also revealed
some unexpected observations. Profiling
dasatinib lead to the discovery of
MAP2K5 as a novel target, something
previous drug screens had failed to do,
suggesting the native conformation of
MAP2K5 reflects the true binding inter-
actions with this inhibitor. Lastly, the
analysis of Raf kinase inhibitors further
illustrates the advantage of the KiNativ
approach in inhibitor analysis. The au-
thors profiled Raf kinase inhibitors for
binding to recombinant or native B-Raf,
inhibition of phospho-ERK1/2, and cell
proliferation. Importantly, large differ-
ences in the inhibitor binding and cellular
efficacy were detected when recombi-
nant B-Raf was analyzed, whereas the
results with native B-Raf more closely
resembled the response in cells. More-
over, the observation that ATP probe
labeling increased in A-Raf and Raf-1 in
response to Raf inhibitor (PLX4720 and
others) further suggests that, consistent
with the paradoxical activation of Raf-1
by these compounds, inhibitor-induced
conformational changes were detected
by this method.
Overall, there are many notable advan-
tages to the KiNativ approach. The most
significant of these is the ability to profile
kinome responses of native endogenous
kinases and to obtain information
regarding the true binding properties of
kinase inhibitors in a cellular context. In
addition, KiNativ may enable identifica-
tion of changes that increase or decrease
the affinity of the active site for the bio-
tinylated probes. As suggested with
PLX4720 treatment of A-Raf, this may684 Chemistry & Biology 18, June 24, 2011 ªrequire the optimal positioning of active
site residues to facilitate probe labeling.
Furthermore, it is likely that other unex-
pected inhibitor targets such as MAP2K5
will be identified when assayed in their
native conformations.
One potential disadvantage of this
method is that it requires sophisticated
methods of mass spectrometry as well
as knowledge of the protein/peptide
sequence and desired ion fragments for
analysis. The acyl phosphate probe must
also react with one or more of the
conserved lysines in the catalytic pocket
of the kinase. In contrast, affinity capture
of kinases using immobilized inhibitors
(Godl et al., 2003; Bantscheff et al.,
2007; Sharma et al., 2009) is more adapt-
able to standard methods of mass spec-
trometry. The method described here
also requires the preparation of cell
lysates and is dependent on the efficacy
of the ATP/ADP probe chemical reactions
that requires the removal of endogenous
ATP. These treatments may disrupt
normal protein-protein interactions and
allow proteolysis, dephosphorylation or
other modifications to occur. In light of
these limitations, it is unlikely that any
one method will be sufficient for all
kinase-inhibitor analyses. With that said,
the authors have successfully applied
this technology to broadly analyze large
numbers of kinases in parallel and
demonstrated the efficacy of this unique
approach to gain new insight into kinase
inhibitor specificity.
In conclusion, by demonstrating that for
several inhibitors the binding profiles
closely corresponded to their cellular
activity, it is evident that KiNativ repre-
sents a significant advance over kinome
and kinase inhibitor profiling that relies2011 Elsevier Ltd All rights reservedexclusively on the analysis of purified
components. Given the utility of kinase
inhibitors as research tools and promising
agents for molecular-targeted therapy,
the opportunity to characterize their inter-
actions with native endogenous kinases
undoubtedly represents a significant
step forward.REFERENCES
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